IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-24319-x.html
   My bibliography  Save this article

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

Author

Listed:
  • Alberto Lleó

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Henrik Zetterberg

    (Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg
    Sahlgrenska University Hospital
    UK Dementia Research Institute at UCL
    UCL Institute of Neurology)

  • Jordi Pegueroles

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Thomas K. Karikari

    (Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg)

  • María Carmona-Iragui

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED)
    Barcelona Down Medical Center, Fundació Catalana Síndrome de Down)

  • Nicholas J. Ashton

    (Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg
    University of Gothenburg
    Institute of Psychiatry, Psychology and Neuroscience, King’s College London
    NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation)

  • Victor Montal

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Isabel Barroeta

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Juan Lantero-Rodríguez

    (Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg)

  • Laura Videla

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED)
    Barcelona Down Medical Center, Fundació Catalana Síndrome de Down)

  • Miren Altuna

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Bessy Benejam

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED)
    Barcelona Down Medical Center, Fundació Catalana Síndrome de Down)

  • Susana Fernandez

    (Barcelona Down Medical Center, Fundació Catalana Síndrome de Down)

  • Silvia Valldeneu

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Diana Garzón

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Alexandre Bejanin

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Maria Florencia Iulita

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Valle Camacho

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona)

  • Santiago Medrano-Martorell

    (Hospital del Mar-Universitat Autònoma Barcelona (UAB))

  • Olivia Belbin

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Jordi Clarimon

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Sylvain Lehmann

    (The Institute for Neurosciences of Montpellier, Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, INSERM)

  • Daniel Alcolea

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Rafael Blesa

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED))

  • Kaj Blennow

    (Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg
    Sahlgrenska University Hospital)

  • Juan Fortea

    (Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona
    Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED)
    Barcelona Down Medical Center, Fundació Catalana Síndrome de Down)

Abstract

Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer’s disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73–0.87] and 0.92 [95% CI 0.89–0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.

Suggested Citation

  • Alberto Lleó & Henrik Zetterberg & Jordi Pegueroles & Thomas K. Karikari & María Carmona-Iragui & Nicholas J. Ashton & Victor Montal & Isabel Barroeta & Juan Lantero-Rodríguez & Laura Videla & Miren A, 2021. "Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome," Nature Communications, Nature, vol. 12(1), pages 1-8, December.
    • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24319-x
    DOI: 10.1038/s41467-021-24319-x
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-24319-x
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-021-24319-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24319-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.